Gabapentin Capsule
Product Images NDC 68788-7838

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7838). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules, Usp 400mg

Gabapentin Capsules, USP 400 mg oral capsule label from Preferred Pharmaceuticals Inc. The label states it is a generic for Neurontin and includes storage instructions, manufacturer ScieGen Pharmaceuticals, Inc., and a barcode. Directions for use are printed in English and Spanish on a bright yellow background.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. Gabapentin shows a decreasing pain score trend while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease over time for both Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' illustrating response rates in two studies. The y-axis shows percentage responders from 0% to 100%. Study 1 compares PBO (12%) and GBP 3600 (29%). Study 2 compares PBO (14%), GBP 1800 (32%), and GBP 2400 (34%) with significance levels indicated by ** and *** for p-values <0.01 and <0.001 respectively.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A mathematical formula calculating creatinine clearance (CLCr), which factors age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplier of 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram of the active ingredient Gabapentin, showing its molecular arrangement with a cyclohexane ring and amine and carboxyl functional groups.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot comparing difference percentages against daily dose in mg for three studies labeled as Study a, Study b, and Study c. The x-axis shows daily doses ranging from 600 to 1800 mg, and the y-axis shows difference percentages from 2% to 22%. Data points for each study are marked differently to distinguish study results across doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.